Clinical Trials Directory

We are doing this study to find out if the combination of an experimental drug called ONC201 (the study drug) with paxalisib is an effective option for patients with a diffuse midline glioma (DMG). We also want to see how much of these drugs are absorbed by tumor tissue in patients with brain tumors.

This study is for people with type 1 diabetes (T1D). Their immune system attacks cells in the body that make insulin. A new treatment called GNTI-122 is made from their own blood cells and may help stop this attack. People will be in one of three groups: low dose, high dose, or high dose with another medicine called rapamycin. The study includes several visits to check if the treatment works and is safe.

The person in the study will take part for about 5 years and 2 months. During this time, doctors will check their health in many ways. These checks include a physical exam, blood tests, breathing tests, heart tests, muscle scans, and other special tests. The study has four parts: 1. First, there is a screening visit to make sure the person can join. 2. Next, the person will get the study medicine. 3. Then, there is an active observation period for 1 year. During this time, there will be about 19 visits at home and at the clinic. 4. Finally, there is a long-term follow-up for 4 years. This part has 8 visits.

We are doing this study to find out if adding azithromycin to the routine single antibiotic preventative therapy can lower the risk of developing infections after a cesarean delivery.

We are doing this study to learn more about how 2 different classes of diabetes medications help lower the risk of heart disease. The types of diabetes medications that have been shown to reduce the risk of new or worsening heart disease are SGLT2 inhibitors and GLP-1 receptor agonists. We don't know which of these drugs might be preferable to reduce heart disease risk for diabetes patients, and we hope this study can help us find out which drug(s) may be the most appropriate for most patients.